Table 1.
Characteristics of patients treated with platinum in combination with 5-FU plus cetuximab.
Table 2.
Treatment characteristics after 3 or 6 cycles of platinum, 5-fluourouracil and cetuximab.
Table 3.
Treatment characteristics according to platinum used for CF+ cetuximab.
Table 4.
Grade 3 and/or grade 4 adverse effects observed according to CTCAE version 4.0.
Figure 1.
Show PFS of all patient treated with platinum +5-FU +cetuximab (A); and stratified by platinum (B): carboplatin +5-FU+cetuximab versus cisplatin +5-FU+cetuximab.
Analysis was performed using log-rank test. Abbreviations: PFS stands for progression-free-survival; C stands for platinum (carboplatin or cisplatin); 5-FU stands for 5-fluourouracil.
Figure 2.
Show OS survival of all patients treated with platinum +5-FU+cetuximab (A); and stratified by platinum (B): carboplatin +5-FU+cetuximab versus cisplatin +5-FU+cetuximab.
Analysis was performed using log-rank test. Abbreviations: OS stands for overall-survival; C stands for platinum (carboplatin or cisplatin); 5-FU stands for 5-fluourouracil.